Top

Published in:

01-09-2008

Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival

Authors: Volga S. Syamala, Leelakumari Sreeja, Vani Syamala, Praveenkumar B. Raveendran, Rajan Balakrishnan, Ratheesan Kuttan, Ravindran Ankathil

Published in: Familial Cancer | Issue 3/2008

Abstract

Identifying genes associated with familial inheritance of breast cancer continues to be a major goal of current research as the known high penetrance genes could be attributable for only a small percentage of the risk. So, it is hypothesized that the low penetrance genes may also modify the risk for familial breast cancer. In the present case–control study, undertaken to examine the influence of polymorphisms of GSTs in familial and sporadic breast cancer susceptibility, 597 women including 222 sporadic breast cancer patients, 125 familial breast cancer patients and 250 females with no history of cancer as controls were genotyped by PCR based methods. Odds Ratios (ORs) and 95% Confidence Intervals (95%CIs) were calculated by unconditional logistic regression adjusted to age. Interestingly, GSTM1 deletion was found to be significantly associated only with familial breast cancer (OR = 2.0; 95%CI = 1.252–3.128) while GSTT1 was associated only with sporadic breast cancer (OR = 2.3; 95%CI = 1.336–3.970). GSTP1 Ile¹⁰⁵Val polymorphism was associated neither with sporadic nor familial breast cancer susceptibility (P value > 0.05). The GST genotypes did not have any effect on the survival of both familial and sporadic breast cancer patients. However, familial breast cancer patients with GSTM1 null genotype had a relative risk of 0.42 (95%CI = 0.18–0.97) for an advanced disease stage. The results indicate that, in addition to the known high penetrance genes, certain low penetrance genes may also play a role, in the familial inheritance of breast cancer. It is also noticed that all the polymorphisms associated with sporadic breast cancer are not associated with familial breast cancer.

Ali-Osman F, Akande O, Antoun G et al (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012PubMedCrossRef

Ambrosone CB, Freudenheim JL, Graham S et al (1995) Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 55:3483–3485PubMed

Ambrosone CB, Sweeney C, Coles BF et al (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 19:7130–7135

Bell DA, Taylor JA, Paulson DF et al (1993) Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85:1159–1164PubMedCrossRef

Chacko P, Joseph T, Mathew BS et al (2005) Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mutat Res 581:153–163PubMed

Chen CL, Liu Q, Relling MV (1996) Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 6:187–191PubMedCrossRef

Curran JE, Weinstein SR, Griffiths LR (2000) Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and breast cancer susceptibility. Cancer Lett 153:113–120PubMedCrossRef

DeMichele A, Aplenc R, Botbyl J et al (2005) Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 23:5552–5559PubMedCrossRef

Easton DF (1999) How many more breast cancer predisposition genes are there? Breast Cancer Res 1:14–17PubMedCrossRef

10.

Egan KM, Cai Q, Shu XO et al (2004) Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers Prev 13:197–204PubMedCrossRef

11.

Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast cancer linkage consortium. Am J Hum Genet 62:676–689PubMedCrossRef

12.

Garcia-Closas M, Kelsey KT, Hankinson SE et al (1999) Glutathione S-transferase mu and theta polymorphisms and breast cancer susceptibility. J Natl Cancer Inst 91:1960–1964PubMedCrossRef

13.

Gudmundsdottir K, Tryggvadottir L, Eyfjord JE (2001) GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev 10:1169–1173PubMed

14.

Hamajima N, Takezaki T, Tajima K (2002) Allele Frequencies of 25 Polymorphisms pertaining to cancer risk for Japanese, Koreans and Chinese. Asian Pac J Cancer Prev 3:197–206PubMed

15.

Harries LW, Stubbins MJ, Forman D et al (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18:641–644PubMedCrossRef

16.

Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445–600PubMedCrossRef

17.

Helzlsouer KJ, Selmin O, Huang HY et al (1998) Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer. J Natl Cancer Inst 90:512–518PubMedCrossRef

18.

IARC (1989) IARC Monographs on the evaluation of carcinogenic risks to humans, Vol 43, diesel and gasoline engine exhausts and some nitroarenes. Lyon, 41–185

19.

Joseph T, Kusumakumary P, Chacko P et al (2004) Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 43:560–567PubMedCrossRef

20.

Kelsey KT, Hankinson SE, Colditz GA et al (1997) Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 6:511–515PubMed

21.

Ketterer B (1998) Glutathione S-transferases and prevention of cellular free radical damage. Free Radic Res 28:647–658PubMedCrossRef

22.

Khedhaier A, Remadi S, Corbex M et al (2003) Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br J Cancer 89:1502–1507PubMedCrossRef

23.

Kim SU, Lee KM, Park SK et al (2004) Genetic polymorphism of glutathione S-transferase P1 and breast cancer risk. J Biochem Mol Biol 37:582–585PubMed

24.

Lizard-Nacol S, Coudert B, Colosetti P et al (1999) Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res 1:81–87PubMedCrossRef

25.

Millikan R, Pittman G, Tse CK, Savitz DA, Newman B, Bell D (2000) Glutathione S-transferases M1, T1, and P1 and breast cancer. Cancer Epidemiol Biomarkers Prev 9:567–573PubMed

26.

Mitrunen K, Jourenkova N, Kataja V et al (2001) Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 10:229–236PubMed

27.

Nathanson KL, Weber BL (2001) Other breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet 10:715–720PubMedCrossRef

28.

Nedelcheva KV, Andersen TI, Erikstein B et al (1998) Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics 8:441–447CrossRef

29.

Park SK, Yoo KY, Lee SJ et al (2000) Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics 10:301–309PubMedCrossRef

30.

Pemble S, Schroeder KR, Spencer SR et al (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300(Pt 1):271–276PubMed

31.

Ryberg D, Skaug V, Hewer A et al (1997) Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18:1285–1289PubMedCrossRef

32.

Samson M, Swaminathan R, Rama R et al (2007) Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India. Asian Pac J Cancer Prev 8(2):253–257PubMed

33.

Seidegard J, Vorachek WR, Pero RW et al (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293–7297PubMedCrossRef

34.

Serova OM, Mazoyer S, Puget N et al (1997) Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486–495PubMed

35.

Sreeja L, Syamala V, Hariharan S et al (2005) Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J Hum Genet 50:618–627PubMedCrossRef

36.

Sreelekha TT, Ramadas K, Pandey M et al (2001) Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 37:593–598PubMedCrossRef

37.

Strange RC, Spiteri MA, Ramachandran S et al (2001) Glutathione-S-transferase family of enzymes. Mutat Res 482:21–26PubMed

38.

Sundberg K, Johansson AS, Stenberg G et al (1998) Differences in the catalytic efficiencies of allelic variants of glutathione transferase P1–1 towards carcinogenic diol epoxides of polycyclic aromatic hydrocarbons. Carcinogenesis 19:433–436PubMedCrossRef

39.

Sweeney C, Ambrosone CB, Joseph L et al (2003) Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103:810–814PubMedCrossRef

40.

Yang G, Shu XO, Ruan ZX et al (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58PubMedCrossRef

41.

Zimniak P, Nanduri B, Pikula S et al (1994) Naturally occurring human glutathione S-transferase GSTP1–1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 224:893–899PubMedCrossRef

Title: Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival
Authors: Volga S. Syamala
Leelakumari Sreeja
Vani Syamala
Praveenkumar B. Raveendran
Rajan Balakrishnan
Ratheesan Kuttan
Ravindran Ankathil
Publication date: 01-09-2008
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2008
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-007-9177-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

Prolactin and systemic malignancies: a close association

Muir-Torre Syndrome: expanding the genotype and phenotype—a further family with a MSH6 mutation

Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers

The extracolonic cancer spectrum in females with the common ‘South African’ hMLH1 c.C1528T mutation

Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk

Tumor histology helps to identify Lynch syndrome among colorectal cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer